Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$949139.0.

  • Gain Therapeutics' Change in Accured Expenses rose 4879.68% to -$949139.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $258582.0, marking a year-over-year increase of 13724.03%. This contributed to the annual value of $274889.0 for FY2024, which is 13962.66% up from last year.
  • Latest data reveals that Gain Therapeutics reported Change in Accured Expenses of -$949139.0 as of Q3 2025, which was up 4879.68% from $151651.0 recorded in Q2 2025.
  • Over the past 5 years, Gain Therapeutics' Change in Accured Expenses peaked at $1.7 million during Q1 2022, and registered a low of -$1.9 million during Q3 2024.
  • In the last 5 years, Gain Therapeutics' Change in Accured Expenses had a median value of $3456.0 in 2021 and averaged $67072.4.
  • Per our database at Business Quant, Gain Therapeutics' Change in Accured Expenses surged by 5033816.55% in 2022 and then plummeted by 392098.26% in 2024.
  • Gain Therapeutics' Change in Accured Expenses (Quarter) stood at -$589191.0 in 2021, then tumbled by 39.6% to -$822482.0 in 2022, then decreased by 24.9% to -$1.0 million in 2023, then soared by 94.35% to -$58070.0 in 2024, then plummeted by 1534.47% to -$949139.0 in 2025.
  • Its last three reported values are -$949139.0 in Q3 2025, $151651.0 for Q2 2025, and $1.1 million during Q1 2025.